Trading of Adicet Bio was halted at 09:30 AM EST due to "LULD Pause". NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis $7.16 -1.86 (-20.60%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Adicet Bio Stock (NASDAQ:ACET) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adicet Bio alerts:Sign Up Key Stats Today's Range$6.43▼$7.9650-Day Range$7.79▼$9.7352-Week Range$6.01▼$17.44Volume935,725 shsAverage Volume135,404 shsMarket Capitalization$67.04 millionP/E RatioN/ADividend YieldN/APrice Target$46.80Consensus RatingModerate Buy Company Overview Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. Its platform is based on gamma delta T cells, a type of immune cell that may be engineered to recognize and attack tumor cells while potentially offering advantages associated with off-the-shelf cell therapies. The company’s pipeline has included investigational CAR T-cell products designed to target specific cancer antigens, including ADI-001, an anti-CD19 therapy developed for B-cell malignancies. Adicet’s research also focuses on applying its cell-engineering and manufacturing technologies to develop additional treatments for hematologic cancers and solid tumors. Founded in 2014, Adicet Bio is headquartered in the United States and conducts research and development activities aimed at advancing allogeneic, or donor-derived, cell therapies. Its products remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Adicet Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreACET MarketRank™: Adicet Bio scored higher than 75% of companies evaluated by MarketBeat, and ranked 173rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAdicet Bio has a consensus price target of $46.80, representing about 418.8% upside from its current price of $9.02.Amount of Analyst CoverageAdicet Bio has only been the subject of 4 research reports in the past 90 days.Read more about Adicet Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adicet Bio are expected to grow in the coming year, from ($6.76) to ($5.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adicet Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.01% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently increased by 7.65%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth.Read more about Adicet Bio's dividend. News and Social Media2.8 / 5News Sentiment0.52 News SentimentAdicet Bio has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Adicet Bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have not sold or bought any company stock.Percentage Held by Insiders3.40% of the stock of Adicet Bio is held by insiders.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adicet Bio's insider trading history. Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACET Stock News HeadlinesAdicet Bio Shares Rise Ahead Of Prula-cel Clinical Data Update1 hour ago | rttnews.comAdicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients1 hour ago | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 28 at 1:00 AM | Stansberry Research (Ad)Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis3 hours ago | businesswire.comWall Street Zen Upgrades Adicet Bio (NASDAQ:ACET) to "Hold"September 26 at 1:19 AM | americanbankingnews.comAdicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisSeptember 25 at 4:00 PM | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Receives $46.80 Consensus Target Price from BrokeragesSeptember 23, 2026 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Adicet Bio (NASDAQ:ACET)September 20, 2026 | americanbankingnews.comSee More Headlines ACET Stock Analysis - Frequently Asked Questions How have ACET shares performed this year? Adicet Bio's stock was trading at $8.42 on January 1st, 2026. Since then, ACET shares have increased by 7.1% and is now trading at $9.02. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by $0.30. When did Adicet Bio's stock split? Adicet Bio's stock reverse split on the morning of Tuesday, December 30th 2025.The 1-16 reverse split was announced on Friday, December 26th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Adicet Bio IPO? Adicet Bio (ACET) raised $85 million in an initial public offering on Friday, January 26th 2018. The company issued 5,666,667 shares at $14.00-$16.00 per share. Who are Adicet Bio's major shareholders? Top institutional investors of Adicet Bio include Regeneron Pharmaceuticals Inc. (0.65%), Johnson & Johnson (0.24%), Squarepoint Ops LLC (0.16%) and AXQ Capital LP (0.12%). Insiders that own company stock include Ra Capital Management, LP, Orbimed Advisors Llc and Chen Schor. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Company Calendar Last Earnings8/05/2026Today9/28/2026Study update9/28/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ACET's financial health is in the Yellow zone, according to TradeSmith. ACET has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACET CIK1720580 Webwww.adicetbio.com Phone(617) 482-2333FaxN/AEmployees102Year Founded2016Price Target and Rating Average Price Target for Adicet Bio$46.80 High Price Target$90.00 Low Price Target$18.00 Potential Upside/Downside+468.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($11.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$116.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.90% Return on Assets-60.87% Debt Debt-to-Equity Ratio0.01 Current Ratio6.71 Quick Ratio6.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$16.62 per share Price / Book0.50Miscellaneous Outstanding Shares9,361,000Free Float9,043,000Market Cap$77.13 million OptionableOptionable Beta1.58 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ACET) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredUnder $5, Is This Nasdaq Early to America's Next Defense Boom?Small drones costing hundreds of dollars can now rival tanks and equipment worth millions, a shift Ukraine has...i2i Marketing Group, LLC | SponsoredHOST Just Closed Its Major Merger!Host Digital Inc (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp on September 17,...Trading Wire | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredA bill in Congress would require the Treasury to reprice America's gold. Here is what it means for your 401k.The US government still values its gold reserves at $42 an ounce, a price set by Congress back in 1973 and nev...Monetary Gold | SponsoredThe Department of War is on a gold mine's filingsOn May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACET Stock Alerts